Summary Mechanisms of anthracycline resistance have been investigated in a B16 murine melanoma cell subline selected by continuous in vitro exposure to increasing concentrations of doxorubicin (DX) . Altered drug pharmacokinetics were observed in resistant B16 cells as compared to the sensitive counterpart. In fact, cellular DX uptake -as determined by a fluorescence method -was lower in resistant than in sensitive cells. Furthermore, drug efflux rate was shown to be higher in resistant than in sensitive cells; treatment of cells with the metabolic inhibitor sodium azide decreased drug efflux rate in resistant but not in sensitive cells, suggesting the presence of an energy-dependent drug extrusion mechanism in the resistant B16 cells. However, since drug-induced cell killing did not correlate with cellular DX contents in sensitive and resistant cells, drug resistance of B16 subline could not be completely explained by the observed differences in drug pharmacokinetics. Since drug-induced DNA breaks have been related to drug cytotoxicity, DNA cleavage was also measured by alkaline elution methods. The number of DNA breaks produced by DX was decreased in resistant cells as compared to sensitive cells at the same cellular drug accumulation. The results are consistent with the view that anthracycline resistance may be multifactorial and probably arises following multiple biochemical changes. Doxorubicin (DX) is one of the most active chemotherapeutic agents for the treatment of human cancer (Davis & Davis, 1979) . However, tumour cells often develop resistance to antitumour drugs, even in patients who were initially responsive, and this may lead to therapeutic failure (Kaye & Merry, 1985) . Many leukaemia and solid tumour cell lines have been selected for resistance to anthracyclines, in order to study the mechanisms of cellular drug resistance. These experimental models are often resistant not only to the selecting drug but also to other unrelated compounds: this phenomenon is known as multi-drug resistance (MDR) (Wilkoff & Dulmadge, 1978; Chitnis et al., 1982) . Altered drug permeability of the plasma membrane of resistant cells has been generally implied as the mechanism underlying MDR (Inaba et al., 1979; Bates et al., 1985; Siegfried et al., 1985) and MDR is associated with the overproduction of high molecular weight membrane glycoproteins following gene amplification (Van der Blieck et al., 1986; Riordan et al., 1985; Slovak et al., 1986) . However, multiple biochemical modifications may be responsible for MDR, as reduced drug-induced DNA cleavage was observed in resistant cells (Capranico et al., 1986; Glisson et al., 1986) , and overproduction of a 20 Kd cytosolic protein was reported in MDR cells selected with vincristine (Meyers et al., 1985) .
A cell line of murine melanoma B16 was previously selected by continuous in vitro exposure to increasing DX concentrations. As previously described (Supino et al., 1986 , Formelli et al., 1986a , this cell subline was 200 times more resistant to DX than the parental cell line, (ID50 2,000-2,200 versus 10-15ngml-1) and it showed biological and biochemical properties different from those of the parental sensitive cell line both in vitro and in vivo. The aim of the present work was to investigate whether acquired resistance of B16 cells to DX could be associated with altered membrane transport and with differences in drug induced DNA breakage. Experiments to evaluate the mechanisms of drug transport were carried out in Hank's Balanced Salt Solution (HBSS). NaN3 (10 mM) was added 10 min before DX and not removed during drug treatment.
Materials and methods
Efflux was evaluated after 1 h drug treatment. At this time DX was removed, cells washed with ice-cold saline solution and replaced in drug-free HBSS. At different times cells were detached and processed as above. The activity of glucose and NaN3 on DX efflux was evaluated by adding these compounds during drug uptake and/or efflux.
Alkaline elution assay DNA single-strand breaks (SSB) were determined by alkaline elution methods as essentially described by Kohn et al. (1981) and reported elsewhere (Capranico et al., 1986 (Capranico et al., 1986 ) and expressed as rad-equivalents. Table I shows that the maximum efflux was reached after 2 h in both cell lines and only a further slight reduction in the cellular drug content could be observed after 24 h. However, the rate of drug efflux was different being 20% and 50-60% after 45min and 40-50% and 70% after 120min in B16V and B16VDXR cells respectively. Therefore, drug efflux was faster and higher in resistant cells than in sensitive cells. NaN3. Figure 3a shows that both NaN3 (10 mM) and glucose (5.5 mM) do not affect either the uptake or the efflux of DX in B16V cells. On the contrary, an increase of -20% in the DX uptake was observed in B16VDXR cells in the presence of NaN3 (Figure 3b ). This increased uptake seems to be due to the observed decrease of efflux from 74 to 50%. In fact, this value of efflux was restored by the addition of glucose to the culture medium.
Results

Drug
These data suggest different mechanisms of efflux in our two cell lines. Drug extrusion seems to be mainly due to a passive transport in sensitive cells, whereas in resistant cells the efflux is regulated by an active transport. However, an alternative explanation would be an energy-dependent release of drug from intracellular binding sites.
Formation of DNA breaks Since DX resistance could not be completely explained by differences of drug pharmacokinetics between the two cell lines, we examined the formation of DNA-SSB subsequent to drug treatment, since it was shown that reduced DNA cleavage by anthracyclines is associated with acquired drug resistance of P388 leukaemia cells (Capranico et al., 1986; 1987) . DNA-SSB induced by 1 h treatment with DX in sensitive and resistant B16 cells were reported in Figure 4 as a function of cellular drug accumulation. In the range of drug concentrations used, DNA-SSB frequency seemed to be lower in resistant than in sensitive cells at the same cellular drug uptake. On the contrary, y-rays induced the same effects on DNA in the two melanoma cell lines (not shown). Relatively linear alkaline elution curves were expected in these experiments if drug treatment produced predominantly random DNA breakage. On the contrary, in sensitive B16 cells the highest concentration of drug yielded curvilinear elution profiles (not shown). Thus, in this case DNA breaks were probably underestimated, as a significant fraction of cells can be in a non-proliferating state. These results suggest that intracellular drug interactions may also be modified in B16VDXR cells. 
Discussion
In the present study we show that DX resistance of B16VDXR cells is associated with lower drug uptake and retention as compared to B16V cells. Furthermore, biochemical modifications of drug action at intracellular level are likely to be present in resistant cells. At the same extracellular drug concentration the efflux was lower in B16 sensitive cells causing an intracellular drug concentration 7-10 fold higher than in resistant ones. Moreover, the slope of the efflux was faster in resistant than in sensitive cells. Thus, besides a different ratio between the amount of DNA (that is 1 1.6 times higher in resistant than in sensitive cells) and the different drug concentration, a different time of exposure of DNA to DX may be a factor for resistance in these cells.
The results reported in Table I showing a higher and faster drug efflux at high concentrations on both lines indicate that an intracellular binding saturation seems to be reached both in B16V and B16VDXR cells. Moreover, the increase of the intracellular/extracellular ratio of drug concentration at low extracellular drug amounts points out Cellular drug content (,ug 10-6 cells) Figure 4 Relationship between DNA-SSB and cellular drug content in B16V (0) and B16VDXR (0) cells. Cells were exposed to DX for 1 h at 37°C and processed as described in Materials and methods. Each point is the mean of 3 independent determinations + s.e. Our findings on drug uptake agree with those reported on P388 (Inaba et al., 1979) and Ehrlich ascites tumours (Skovsgaard, 1977) . In fact, drug influx in sensitive and resistant cells is independent of energetic metabolism, while drug efflux -at least in resistant cells -is reduced by NaN3, an inhibitor of oxidative phosphorylation. Since the resistant subline has probably arisen by selection of a low percentage of cells already present in the parental sensitive population (Supino et al., 1986) , it is possible that the selection was caused by an enhanced active mechanism of DX extrusion. The DX concentrations used in these in vitro experiments are those achievable in the plasma of mice treated with the drug (Formelli et al., 1986b) . These in vitro studies are of considerable help to investigate the cell drug pharmacokinetic properties, although it is known that other factors like drug metabolism, tumour vascularization, tumour burden, schedule and route of administration may affect the in vivo activity of DX. The present data also show a lack of correlation between cytotoxicity and intracellular drug concentration in the two cell lines. To obtain a 50% of cell survival in resistant cells, it was necessary a total intracellular drug concentration 4-10 fold higher than in sensitive cells. This difference can be partially explained by the previously reported observation (Supino et al., 1986 ) that after a short treatment the intracellular distribution of DX is different, being the nucleus/cytoplasm ratio double in sensitive as compared to resistant cells.
However, since protein-associated DNA breaks induced by intercalating drugs have been related to drug cytotoxicity (Pommier et al., 1985; ) and a decreased effect on DNA has been described in P388 cells resistant to DX as compared to sensitive cells (Capranico et al., 1986; 1987) , we also measured DX-induced DNA-SSB in sensitive and resistant melanoma cells. Though DX-induced DNA-SSB levels are higher in sensitive leukaemia cells than in sensitive B16 melanoma cells, our results show that DNA fragmentation produced by DX is reduced in resistant B16 cell line as compared to sensitive counterpart at the same cellular drug content. This reduction was less marked than that observed in P388 cell system (Capranico et al., 1986; 1987) . It was even less if we consider that the cell volume of B16VDXR cells is 2-fold higher than that of B16V cells. Therefore, in this cell model the reduction of DX-induced cytotoxicity and DNA breaks is probably due to impaired drug uptake. However, it is still possible that a change of drug-DNA interaction may be present in B16VDXR cells. Further studies will better elucidate this point. In conclusion, these results are consistent with the hypothesis that MDR may be multifactorial (Capranico et al., 1987) and probably arises following multiple changes such as altered drug membrane transport, intracellular drug distribution and drug-induced effects on DNA.
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